Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRB1ADRB2ADRB3CYP11B1DPP4FGFR1FGFR2FGFR3FGFR4HRH1JAK1JAK2JAK3KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITNAOPRD1OPRK1OPRM1PPDGFRBPIK3CDSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASMOTYK2polrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC34A1 | Q06495 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | FDPS | P14324 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.30 |
| ▸ | CA4 | P22748 | 2/20 | 0.30 |
| ▸ | CA5A | P35218 | 2/20 | 0.30 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid SCHEMBL29020583 | 0.90 | SLC34A1 (0.58) | SLC34A1LMNAKDM4ECYP2C19KMT2A | |
| Phosphoric Acid SCHEMBL8070208 | 0.90 | SLC34A1 (0.58) | SLC34A1LMNAKDM4ECYP2C19KMT2A | |
| Phosphoric Acid SCHEMBL8470574 | 0.90 | SLC34A1 (0.58) | SLC34A1LMNAKDM4ECYP2C19KMT2A | |
| Phosphoric Acid SCHEMBL1136325 | 0.90 | SLC34A1 (0.73) | SLC34A1LMNAKDM4ECYP2C19KMT2A | |
| Phosphoric Acid SCHEMBL3917721 | 0.90 | SLC34A1 (0.58) | SLC34A1LMNAKDM4ECYP2C19KMT2A | |
| Phosphoric Acid SCHEMBL7215415 | 0.90 | SLC34A1 (0.58) | SLC34A1LMNAKDM4ECYP2C19KMT2A | |
| Phosphoric Acid SCHEMBL78045 | 0.90 | SLC34A1 (0.58) | SLC34A1LMNAKDM4ECYP2C19KMT2A | |
| Phosphoric Acid SCHEMBL1698246 | 0.90 | SLC34A1 (0.58) | SLC34A1LMNAKDM4ECYP2C19KMT2A | |
| Phosphoric Acid SCHEMBL2779192 | 0.90 | SLC34A1 (0.58) | SLC34A1LMNAKDM4ECYP2C19KMT2A | |
| Phosphoric Acid SCHEMBL28948531 | 0.90 | SLC34A1 (0.58) | SLC34A1LMNAKDM4ECYP2C19KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230285276-A1 | Implantable Medical Device for the Delivery of Aromatase Inhibitor | CELANESE EVA PERFORMANCE POLYMERS LLC | 2023-09-14 | — | — | US | disclosed |
| US-20230263724-A1 | Intravaginal Ring Device for the Delivery of Aromatase Inhibitor | CELANESE EVA PERFORMANCE POLYMERS LLC | 2023-08-24 | — | — | US | disclosed |
| US-20230104358-A1 | Refillable Implantable Device for Delivering a Drug Compound | CELANESE EVA PERFORMANCE POLYMERS LLC | 2023-04-06 | — | — | US | disclosed |
| US-20230047191-A1 | Implantable Medical Device for the Delivery of Bisphosphonate | CELANESE EVA PERFORMANCE POLYMERS LLC | 2023-02-16 | — | — | US | disclosed |
| EP-3150235-B1 | BONE FILLER COMPOSITION | DEPUY INT LTD (GB) | 2018-08-01 | — | — | EP | disclosed |
| US-20180110899-A1 | BONE FILLER COMPOSITION | DEPUY INTERNATIONAL LIMITED (GB) | 2018-04-26 | — | — | US | disclosed |
| EP-3150235-A1 | BONE FILLER COMPOSITION | Depuy International Limited (GB) | 2017-04-05 | — | — | EP | disclosed |
| EP-2804636-B1 | BONE FILLER COMPOSITION | DEPUY INT LTD (GB) | 2016-11-30 | — | — | EP | disclosed |
| US-20140370100-A1 | BONE FILLER COMPOSITION | DEPUY INTERNATIONAL LIMITED (GB) | 2014-12-18 | — | — | US | disclosed |
| EP-2804636-A1 | BONE FILLER COMPOSITION | DePuy International Limited (GB) | 2014-11-26 | — | — | EP | disclosed |
| US-20040028611-A1 | Non-isotopic detection of osteoblastic activity in vivo using modified bisphosphonates | BETH ISRAEL DEACONESS MEDICAL CENTER, OF THE ENTIRE INERST. | 2004-02-12 | — | — | US | disclosed |
| EP-1365770-A2 | DEVICES AND METHODS FOR MANAGEMENT OF BONE DENSITY | Durect Corporation (US) | 2003-12-03 | — | — | EP | disclosed |
| EP-1341557-A2 | NON-ISOTOPIC DETECTION OF OSTEOBLASTIC ACTIVITY IN VIVO USING MODIFIED BISPHOSPHONATES | Beth Israel Deaconess Medical Center (US) | 2003-09-10 | — | — | EP | disclosed |
| EP-1131100-B1 | THERAPEUTIC COMPOSITIONS FOR METABOLIC BONE DISORDERS OR BONE METASTASES COMPRISING A PHOTOSENSITIZER AND A BISPHOSPHONATE | LIGHT SCIENCES CORP (US) | 2003-03-12 | — | — | EP | disclosed |
| US-20030018371-A1 | Compositions and methods for the treatment of metabolic bone disorders and bone metastases | LIGHT SCIENCES CORPORATION | 2003-01-23 | — | — | US | disclosed |
| US-20020151876-A1 | Devices and methods for management of bone density | DURECT CORPORATION | 2002-10-17 | — | — | US | disclosed |
| WO-2002062352-A2 | DEVICES AND METHODS FOR MANAGEMENT OF BONE DENSITY | DURECT CORPORATION (US) | 2002-08-15 | — | — | WO | disclosed |
| WO-2002038190-A2 | NON-ISOTOPIC DETECTION OF OSTEOBLASTIC ACTIVITY IN VIVO USING MODIFIED BISPHOSPHONATES | BETH ISRAEL DEACONESS MEDICAL CENTER (US) | 2002-05-16 | — | — | WO | disclosed |
| EP-1131100-A2 | THERAPEUTIC COMPOSITIONS FOR METABOLIC BONE DISORDERS OR BONE METASTASES | Light Sciences Corporation (US) | 2001-09-12 | — | — | EP | disclosed |
| WO-2000041725-A2 | THERAPEUTIC COMPOSITIONS FOR METABOLIC BONE DISORDERS OR BONE METASTASES | LIGHT SCIENCES CORPORATION (US) | 2000-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040028611-A1 | Non-isotopic detection of osteoblastic activity in vivo using modified bisphosphonates | SOST, ACP3, PHPT1 | SLC34A1 34/4885LMNA 1951/4885KDM4E 3447/4885 |
| US-20230104358-A1 | Refillable Implantable Device for Delivering a Drug Compound | GNRHR, RCOR1, PRLHR | SLC34A1 2516/4885LMNA 1800/4885KDM4E 3211/4885 |
| US-20230047191-A1 | Implantable Medical Device for the Delivery of Bisphosphonate | PGM2, ACADM, MVD | SLC34A1 607/4885LMNA 4369/4885KDM4E 3290/4885 |
| US-20230285276-A1 | Implantable Medical Device for the Delivery of Aromatase Inhibitor | CYP19A1, HSD17B11, ESR1 | SLC34A1 3816/4885LMNA 3748/4885KDM4E 1574/4885 |
| US-20230263724-A1 | Intravaginal Ring Device for the Delivery of Aromatase Inhibitor | CYP19A1, HSD17B11, CYP17A1 | SLC34A1 4437/4885LMNA 3464/4885KDM4E 1167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.